Corbus Pharmaceuticals Holdings closed at $3.57 on Nov 4, down 7.75%, within 0.0% of its 52-week closing low. Volume of 2.0M shares was 1.75× its 20-day average (above normal).
Split-adjusted performance: -38.2% over one month, -67.3% over six months, -71.0% over one year.
Short interest was 2.7M shares at the Oct 15 settlement, down 11.1% from the prior report (14.6% of float, 2.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | Compare |
| PMVPPMV Pharmaceuticals | $1.33 | −3.99% | −8.6% | — | — | — | $70.8M | Compare |
| MNOVMedicinova | $1.45 | +2.11% | 0.0% | +240.6% | −504.8% | — | $71.4M | Compare |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
| CINGCingulate | $4.56 | −3.39% | −14.4% | — | — | — | $66.3M | Compare |
| RANIRani Therapeutics Holdings | $0.5728 | +3.06% | −40.3% | — | −432.7% | — | $66.1M | Compare |
| COYACoya Therapeutics | $3.08 | −0.96% | −27.4% | +49.0% | −2723.4% | — | $72.3M | Compare |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
